Nupro deleting OsteofleX supplement swelling, stiffness treatment claims at FDA's request.
This article was originally published in The Tan Sheet
Executive Summary
NUPRO DELETING OSTEOFLEX SWELLING AND STIFFNESS TREATMENT CLAIMS after receiving a Jan. 21 "courtesy letter" from FDA's Office of Special Nutritionals stating that certain claims for the dietary supplement are unapproved drug claims subject to additional regulation. "The statements that you are making for this product suggest...it is intended to treat, prevent or mitigate degenerative and/or other joint diseases and conditions and to treat muscle or mitigate muscle conditions," the letter states. Companies are required to file their structure/function claims with FDA within 30 days of marketing a dietary supplement product under the Dietary Supplement Health & Education Act.